

Contents

1	Anatomy and Normal Histology of the Prostate Pertinent to Biopsy Practice.....	1
1.1	Anatomy of Normal Prostate.....	1
1.2	Anatomy and Disease Preference of Three Zones of the Prostate	1
1.3	Histology of Normal Prostate.....	2
1.4	Immunophenotype of Prostate Glandular Cells	5
1.5	Histology of Three Zones of Normal Prostate Glands, Other Intraprostatic Structures, and Their Mimics.....	6
1.6	Histologic Variations of Normal Prostate Tissue	8
	References	9
2	Prostate Needle Biopsy Sampling Techniques: Impact on Pathological Diagnosis	11
2.1	Biopsy Techniques for Prostate Cancer Detection and Its Impact on Pathological Diagnosis	11
2.2	Transrectal and Transperineal Biopsy Approaches for Prostate Cancer Detection	12
2.3	Biopsy Parameters That Impact Prostate Cancer Detection Rate in Prostate Needle Biopsy	13
2.4	Future Trends in Prostate Biopsy Sampling and Its Clinical Applications	13
	References	13
3	Diagnosis of Limited Cancer in Prostate Biopsy	15
3.1	General Approach to Prostate Needle Biopsy Evaluation.....	15
3.2	Histological Features Considered Specific for and Diagnostic of Cancer	15
3.3	Major and Minor Histological Features of Prostate Cancer in Biopsy	17
3.4	Benign Conditions That Cause Architectural and Cytological Atypia	23
3.5	Quantitative Threshold for Diagnosing Limited Cancer in Biopsy.....	24
3.6	Histological Features For and Against Cancer Diagnosis in Biopsy	26
3.7	A Practical Approach to Diagnosis of Limited Cancer in Needle Biopsy	26
	References	27
4	Immunohistochemistry in Prostate Biopsy Evaluation	29
4.1	Commonly Used Immunohistochemical Markers for Diagnosis of Prostate Cancer in Biopsy	29
4.2	Basal Cell Markers	30
4.3	α -Methacyl-coA-Racemase (AMACR, P504S).....	34
4.4	ERG Protein	37
4.5	Antibody Cocktails.....	38
4.6	Differential Diagnosis of Prostate Cancer by Immunohistochemistry.....	38

4.7	Practical Guideline for Using Immunohistochemistry in Workup of Prostate Biopsies	39
	References	39
5	Contemporary Approach to Gleason Grading of Prostate Cancer	41
5.1	Significance of Gleason Grading in Prostate Cancer Management	42
5.2	Prostate Cancer Nomograms Recurrence Categories and Prediction Models	42
5.3	Current Concepts of Gleason Grading	44
5.4	Contemporary Gleason Pattern 1	44
5.5	Contemporary Gleason Pattern 2	44
5.6	Contemporary Gleason Pattern 3	45
5.7	Contemporary Gleason Pattern 4	46
5.8	Gleason Grading of Cribriform Carcinomas	48
5.9	Contemporary Gleason Pattern 5	48
5.10	Gleason Grading of Unusual “Variant” Histology Types and Patterns	49
5.11	Gleason Grading in the Setting of Multiple Cores with Prostate Cancer of Different Gleason Patterns	52
5.12	Tertiary Pattern 5 in Prostate Biopsy	52
5.13	Recommendations for Gleason Grading in the Post-therapy Setting	52
5.14	Impact of ISUP-modified Gleason Grading System	52
5.15	Problem Areas in Gleason Grading and Future Trends	54
	References	54
6	Histologic Variants of Prostate Carcinoma	57
6.1	Histological Variants of Prostate Carcinoma	57
6.2	Histologic Variants of Prostate Carcinoma Mimicking Benign Lesions	57
6.3	Foamy Gland Carcinoma	57
6.4	Pseudohyperplastic Carcinoma	59
6.5	Prostate Adenocarcinoma with Atrophic Features	61
6.6	Prostate Adenocarcinoma with Glomeruloid Features	63
6.7	Ductal Adenocarcinoma	64
6.8	Mucinous (Colloid) Carcinoma	66
6.9	Small Cell Neuroendocrine Carcinoma	68
6.10	Approach to Neuroendocrine Differentiation in Prostate Cancer	70
6.11	Sarcomatoid Carcinoma (Carcinosarcoma)	71
6.12	Urothelial Carcinoma	72
6.13	Squamous and Adenosquamous Cell Carcinoma	73
6.14	Signet Ring Cell Carcinoma	75
6.15	Adenoid Cystic Basal Cell Carcinoma	76
	References	77
7	Benign Mimics of Prostate Carcinoma	79
7.1	Classification of Benign Mimics of Prostate Carcinoma using Architectural Pattern-Based Approach	80
7.2	Histological Features Commonly Associated with Benign Mimics	81
7.3	Atypical Morphological Features Commonly Encountered in Various Benign Mimics of Prostate Cancer	82
7.4	Seminal Vesicle/Ejaculatory Duct Epithelium	82
7.5	Verumontanum Mucosal Gland Hyperplasia	83
7.6	Cowper’s Glands	84
7.7	Mesonephric Remnant Hyperplasia	85

7.8	Mucinous Metaplasia	86
7.9	Morphologic Classification of Focal Atrophy Lesions	86
7.10	Partial Atrophy	88
7.11	Postatrophic Hyperplasia.....	90
7.12	Adenosis (Atypical Adenomatous Hyperplasia).....	92
7.13	Basal Cell Hyperplasia.....	94
7.14	Diagnostic Approach to Prostate Basal Cell Lesions.....	97
7.15	Postradiation Atypia in Benign Prostate Glands	98
7.16	Nephrogenic Adenoma.....	100
7.17	Cribriform Proliferations in the Prostate Gland	102
7.18	Central Zone Glands.....	102
7.19	Clear Cell Cribriform Hyperplasia.....	103
7.20	Differential Diagnosis of Prostate Cribriform Lesions	104
7.21	Nonspecific Granulomatous Prostatitis	105
7.22	Malakoplakia.....	107
7.23	Sclerosing Adenosis	108
7.24	Paraganglia	109
7.25	Xanthomatous Infiltrate.....	110
7.26	Benign Mimics of Prostate Cancer: Take-Home Messages	111
	References	111
8	Atypical Cribriform Lesions of the Prostate Gland:	
	Emerging Concepts of Intraductal Carcinoma of the Prostate (IDC-P).....	115
8.1	Intraductal Carcinoma of the Prostate.....	116
8.2	General Approach to the Workup of Atypical Cribriform Lesions in Prostate Needle Biopsy	119
8.3	Comparisons of Clinical, Morphological and Molecular characteristics between cribriform High Grade PIN and IDC-P.....	119
8.4	Pathologic features of IDC-P	120
8.5	Reporting Recommendations for IDC-P	120
	References	120
9	High-Grade Prostatic Intraepithelial Neoplasia (HGPIN).....	121
9.1	Histological Features of Prostatic Intraepithelial Neoplasia (PIN).....	121
9.2	Diagnostic Criteria for HGPIN.....	122
9.3	Clinical Significance of HGPIN.....	127
9.4	Differential Diagnosis of HGPIN.....	127
9.5	Reporting of PIN	130
	References	130
10	Atypical Glands Suspicious for Cancer (ATYP).....	131
10.1	Histological Features Resulting in ATYP	131
10.2	Working up Cases with Atypical Diagnosis.....	137
10.3	Clinical Significance of ATYP	137
	References	138
11	Spindle Cell Lesions of the Prostate Gland.....	139
11.1	Classification of Spindle Cell Lesions of the Prostate	139
11.2	Specialized Stromal Tumors of the Prostate Gland.....	140
11.3	Clinical, Morphologic, and Immunohistochemical Features Suggestive of Prostate Origin of the Spindle Cell Lesions.....	141
11.4	Diagnostic Approach to Spindle Cell Lesions of the Prostate	144

11.5 Immunohistochemical Characteristics of Select Spindle Cell Lesions of the Prostate.	145
References	145
12 Treatment Effect in Benign and Malignant Prostate Tissue	147
12.1 Treatment Modalities for Prostate Lesions.....	147
12.2 Androgen Pathway and Anti-androgen Therapy for Prostate Lesions.....	148
12.3 Histologic Changes Following Androgen-deprivation Therapy in Benign and Malignant Prostate Tissue.....	149
12.4 Histological Changes Associated with Radiation Therapy	151
12.4.1 Histological Changes Following Radiation Therapy in Benign and Malignant Prostate Tissue.....	151
12.4.2 Significance of Postradiotherapy Prostate Biopsy	151
12.5 Histological Changes Associated with Cryotherapy	154
12.6 Histological Changes Associated with Hyperthermia.....	155
References	155
13 Molecular Biology of Prostate Cancer and Emerging Diagnostic and Prognostic Biomarkers	157
13.1 Types of Prostate-Specific Antigen (PSA) Measurements in Clinical Practice	158
13.2 Multistep Model of Prostate Cancer Progression.....	158
13.3 Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer.....	159
13.4 Genes Involved in the Chromosomal Translocations in Prostate Cancer.....	171
13.5 A Model of Molecular Basis of Prostate Cancer Progression Demonstrating Potential Role of <i>ETS</i> Gene Fusions	165
References	166
14 Biopsy Specimen Handling, Processing, Quality Assurance Program	169
14.1 Best Practices for Submission, Handling, and Processing of Prostate Biopsies	170
14.2 Recommendations for tissue submission of transurethral resection specimens	172
14.3 Quality assurance measures known to improve prostate biopsy practice	172
References	172
15 Reporting of Prostate Biopsy.....	173
15.1 Benign Diagnosis	173
15.2 High-grade Prostatic Intraepithelial Neoplasia and Atypical Glands Suspicious for Cancer.....	173
15.3 Adenocarcinoma of the Prostate.....	174
References	180
Index	181